Catalyst Funds Management Pty LTD Supernus Pharmaceuticals, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 800 shares of SUPN stock, worth $29,192. This represents 0.01% of its overall portfolio holdings.
Number of Shares
800Holding current value
$29,192% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
282Shares Held
60.9MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$379 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$224 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$186 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$105 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$96 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.95B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...